Plain-English translation of NCT06897930 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Erythematosus, Systemic research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , which is a type of cell therapy designed to help people with severe lupus that hasn't responded to standard treatments. The medication works by using specially modified immune cells to target and reduce the cells that drive lupus. The study has two parts: first, doctors will test whether the medication is safe and well tolerated, and then they will test whether it actually helps reduce lupus symptoms.
Lupus is a serious autoimmune disease that can severely damage joints, skin, kidneys, and other organs, and some patients don't respond well enough to existing treatments. This trial exists to see if this new type of cell therapy can help patients whose lupus hasn't improved with standard medications.
You likely qualify if…
You likely don't qualify if…
You would receive a single dose of administered as a cell therapy infusion. Before treatment, doctors will collect your own immune cells, modify them in the laboratory, and then return them to your body. You would need to attend multiple study visits for safety monitoring, blood tests, and assessments of how well the treatment is working, with follow-up care continuing over time to ensure the treatment is safe and effective.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States